Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9078 USD 0.81% Market Closed
Market Cap: 167.5m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nektar Therapeutics
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Cash & Cash Equivalents
$30.1m
CAGR 3-Years
-18%
CAGR 5-Years
-18%
CAGR 10-Years
-1%
Johnson & Johnson
NYSE:JNJ
Cash & Cash Equivalents
$8.2B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash & Cash Equivalents
$7.9B
CAGR 3-Years
-16%
CAGR 5-Years
-24%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Cash & Cash Equivalents
$1.1B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Cash & Cash Equivalents
$14.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash & Cash Equivalents
$3.4B
CAGR 3-Years
-4%
CAGR 5-Years
17%
CAGR 10-Years
1%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
167.5m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6997 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Cash & Cash Equivalents?
Cash & Cash Equivalents
30.1m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Cash & Cash Equivalents amounts to 30.1m USD.

What is Nektar Therapeutics's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-1%

Over the last year, the Cash & Cash Equivalents growth was -54%. The average annual Cash & Cash Equivalents growth rates for Nektar Therapeutics have been -18% over the past three years , -18% over the past five years , and -1% over the past ten years .

Back to Top